To the top

Page Manager: Webmaster
Last update: 4/19/2017 1:56 PM

Tell a friend about this page
Print version

Ali Harandi - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Ali Harandi

Researcher

Ali Harandi
Researcher
ali.harandi@microbio.gu.se
+46 31 786 6229
0733-466967

Postal Address: Box 435, 40530 Göteborg
Visiting Address: Medicinaregatan 7A, vån 3 , 41390 Göteborg


Department of Microbiology and Immunology at Institute of Biomedicine (More Information)
Box 435
405 30 Göteborg
Fax: +46 31 786 6210
Visiting Address: Medicinaregatan 7 A , 413 90 Göteborg

Latest publications

Biomarkers of Cutaneous Leishmaniasis
F. Bahrami, Ali M Harandi, S. Riafati
Frontiers in Cellular and Infection Microbiology, Journal article 2018
Journal article

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa
A. Huttner, C. Combescure, S. Grillet, M. C. Haks, E. Quinten et al.
Science Translational Medicine, Journal article 2017
Journal article

Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection
Emilie Bardel, Remi Doucet-Ladeveze, Cyrille Mathieu, Ali M Harandi, Bertrand Dubois et al.
npj Vaccines, Journal article 2016
Journal article

Toxin-Based Mucosal Adjuvants
Ali M Harandi, Nils Y Lycke
Immunopotentiators in Modern Vaccines (Second Edition), Chapter in book 2016
Chapter in book

Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens
N. P. H. Knudsen, A. Olsen, C. Buonsanti, F. Follmann, Yuan Zhang et al.
Scientific Reports, Journal article 2016
Journal article

Ebola vaccine R&D: Filling the knowledge gaps
D. Medaglini, Ali M Harandi, T. H. M. Ottenhof, C. A. Siegrist
Science Translational Medicine, Journal article 2015
Journal article

Showing 1 - 10 of 42

2018

Biomarkers of Cutaneous Leishmaniasis
F. Bahrami, Ali M Harandi, S. Riafati
Frontiers in Cellular and Infection Microbiology, Journal article 2018
Journal article

2017

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa
A. Huttner, C. Combescure, S. Grillet, M. C. Haks, E. Quinten et al.
Science Translational Medicine, Journal article 2017
Journal article

2016

Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection
Emilie Bardel, Remi Doucet-Ladeveze, Cyrille Mathieu, Ali M Harandi, Bertrand Dubois et al.
npj Vaccines, Journal article 2016
Journal article

Toxin-Based Mucosal Adjuvants
Ali M Harandi, Nils Y Lycke
Immunopotentiators in Modern Vaccines (Second Edition), Chapter in book 2016
Chapter in book

Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens
N. P. H. Knudsen, A. Olsen, C. Buonsanti, F. Follmann, Yuan Zhang et al.
Scientific Reports, Journal article 2016
Journal article

2015

Ebola vaccine R&D: Filling the knowledge gaps
D. Medaglini, Ali M Harandi, T. H. M. Ottenhof, C. A. Siegrist
Science Translational Medicine, Journal article 2015
Journal article

Showing 1 - 10 of 42

Page Manager: Webmaster|Last update: 4/19/2017
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/about_the_university/staff/?languageId=100001&userId=xharal&userName=Ali%20M%20Harandi
Utskriftsdatum: 2018-12-14